Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The fact that the professional liability carrier made an unacceptable settlement offer would tell you they think the case has substance. If there's a jury trial there will be a lot of details that will be presented. Cowan will not look good!
This is a very interesting story. In my reading of the many depositions it's clear that Cowan has a huge problem. Cowan was a paperless organization and acquired the firm that provided services to TAUG. The acquired firm lived in paper. With the paper system they were always on top of things. When all the documents got converted to electronic that's when things started falling apart. Taking the time to read the depositions it's clear that important data got lost in the transition. That's where this story begins for the allegations of malpractice. Cowan's actions after the conversion just made things worse. I'd love to be a fly in the courtroom when Cowan is asked about that!
IMUN website link for new website.
https://www.immunetherapeutics.com
Immune Therapeutics has a new website. I don't recall seeing information about CAR-T before. Also, I like the progress chart.
https://www.immunetherapeutics.com/#
Our Progress
Nigeria. 96%
Kenya. 65%
CAR-T. 50%
Cytocom. 50%
Very well put.
There's a story being written by the top management here. It's hard to know for sure where they're taking this but VERY HARD TO IGNORE something is coming that will explain the excessive selling by insiders.
With each press release we are seeing the steps of IMUN's business plan being achieved. It's very obvious there's a good plan, it's achievable and measurable. When investing in a start up those are important indicators. I really think this company knows what it's doing, where they want to go, and how to get there.
We're very close. Nigeria has already approved IMUN to market LDN in the country. Once we have the sign-off on the manufacturing facility we're good to go. The way I see this, Nigeria will be the catalyst to open the door very quickly to other countries in Africa. Nigeria is the largedt country in Africa in terms of population and GDP. They have the most respected FDA in all of Africa and it's internationally recognized. If Nigeria has approved LDN other countries in Africa will respect that their decision was based on good research and trial outcomes. It's encouraging that IMUN is already working on agreements in other markets in Africa.
It's not surprising that insiders would sell to cover tax costs. It's alarming, however, that most have divested from ALL the shares that aren't protected if they decide to do an RS. It's reasonable to be concerned.
Very well put, Rain. I believe the rest of Africa will follow Nigeria close behind, too!
The top insiders own zero common shares. I don't see how any common shareholders can see that as a positive. But that's just me thinking about what might happen next.
I think the question is...isn't it odd that the top insiders have sold ALL of their common shares? That's the crux of it. That would often signal insiders are protecting themselves in preparation of some negative event to come. I hope that's not the case here.
In your prior post you mentioned there is generic use of LDN. This isn't accurate to the extent there is no generic. Some people are trying it on their own though. The only US FDA approved use is for the full dosage naltrexene. Nigeria's version of the FDA, a widely respected agency internationally has given approval for LDN for boosting the immune systems of HIV infected citizens. They have millions of people this could help. We have a tendency to think that the most important events will happen when the US approves a drug. What I find fascinating is that the largest developing country with the highest population in Africa is leading the way and opening the door to widespread, government approved use of LDN. Nigeria is where the launch begins.
Everything I've read about LDN indicates the dosage is specially prepared by a pharmacist prescribed by a physician. There is no generic LDN that I can find and no FDA approved doses for many of the uses people are using it for.
This has been discussed on the board already. How about we just wait to see what happens next.
Trial status conference is tomorrow.
This should settle the Immunovative question.
http://m.marketwired.com/press-release/immunovative-inc-announces-that-name-change-tauriga-sciences-inc-symbol-change-taug-otcqb-imun-1776246.htm
Low dose natrexone LDN has been studied for many years for many potential uses. This video mentions Dr. Birhani, a clinical physician in NY who was the first to recognize its immune system boosting qualities and was a leader in promoting its use. Many of the patents owned by IMUN today are the result of his work and others. This video tells a part of the story. LDN is truly amazing and the really BIG story is only just beginning!
I also read the agreement to say if the company makes 1,500,000 in revenues they must pay off the 150,00 note OR they must pay the 5%. This seems like a very lucrative finance agreement for IMUN. If they've reached 1,500,000 in revenues they should be able to find the 150,000 to pay off this loan.
Legal Cannabis States' Governors Now Support Legalization Thanks to Massive Tax Revenue
With over $1 billion in tax revenue on the line, governors across the country are starting to warm up to legalized cannabis.
https://www.merryjane.com/news/state-governors-support-cannabis-tax-revenue
Excellent news and good progress!
Nice!
Much ado about very little. That's hardly spewing endless crap.
Does anyone have information on how this clinical trial for cervical cancer in Malawi is going? Looks very interesting!
http://www.prnewswire.com/news-releases/immune-therapeutics-inc-through-its-wholly-owned-subsidiary-tni-biotech-international-ltd-initiates-clinical-trial-in-malawi-with-ldn-for-the-prevention-of-cervical-cancer-300317154.html
Immune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer
Where is the endless crap being spewed? Link?
My thoughts are what does it take to get the Nigerians in a plane to the Dominican Republic to inspect the drug manufacturing facility? Heck, I'll buy them a ticket if that's what it takes!
Thanks, dwarren!
I was able to find where the biosynthesis research is being conducted at the University of British Columbia.
http://www.pwias.ubc.ca/profile/vikramaditya-yadav
From Annual Report
On May 21, 2015, the Company commenced the development of its biosynthesis process for the manufacturing of cannabinoids through a research collaboration with Dr. Vikramaditiya Yadav from the Department of Biological and Chemical Engineering at UBC. Utilizing the basis of a vector created by InMed, Dr. Yadav commenced a Research and Development Project titled "The Metabolic Engineering of yeast and bacteria for synthesis of cannabinoids and cannabis derived terpenoids" under a collaborative research contract with InMed. Pursuant to the terms of this collaborative research agreement, InMed and UBC jointly own any resulting intellectual property jointly developed by InMed and UBC, InMed has sole ownership of any intellectual property created solely by InMed, and UBC has sole ownership of any intellectual property created solely by UBC. InMed is currently negotiating a final agreement with UBC to obtain full commercial rights to all intellectual property generated from this program. On June 1, 2016, InMed filed a provisional patent application with the USPTO (No. 62/344,248) entitled "Metabolic Engineering of Cannabinoids".
Doing more DD on InMed. Has anyone been able to find the actual address of InMed's operations. The address on all of their public material shows #350 409 Granville Granville Street, Vancouver, BC. Doing a search on this it appears to be shared space with another OTC pink stock company Standard Graphite. If they have an actual lab where research is being done it's not in this "official" shared office space. I've called and left messages but no one calls me back. Does anyone have info on this?
It will crash back down to earth with no patents and no real drugs in the pipeline anytime soon. This stock is built on hype more than most.
Are you serious? The competition has hundreds of patents and companies knocking on their door for their data. Whatever InMed has it's not generating patents which might protect their IP. InMed is very secretive but the areas we should be able to research and validate - like patents - are non-existent. Announcing "provisional patents" is just another way to keep all of us outsiders in the dark. Even a respected publication like Forbes can be duped!
It's surprising the pps is where it is for this stock. Considering IMUN is just months away from manufacturing and distribution for LDN in Nigeria it's hard to see why there is so little interest. What an I missing in this story?
I think you make a very good point. Teewinot appears to be far ahead of InMed with 212 patents using their biosynthesis process. What does InMed have? If it's the same science it appears Teewinot is winning the race!
https://www.newcannabisventures.com/teewinot-life-sciences-advances-ip-for-biosynthetic-cannabinoid-production/
I'm aware of the stakes in both companies. I guess we will all just have to wait and see.
I hope you're right for the many good people who believed in him. Good luck to you, friend.
I really hope Ryan can resurrect the company. I really do. But taking the company dark was disastrous. To become fully reporting again will require hundreds of thousands of dollars and it's very hard to know what financial shape they are in - but I doubt they have that kind of money sitting around. I was really hoping Ryan could beat all the odds, learn from his mistakes and make LTNC great again! Sadly, I just don't see it happening. Based on what I'm seeing, he's moved on to other lucrative plays that don't include LTNC!
This is the problem I have with the CEO Haas' statement, "but the company is growing so fast that we need a dedicated business professional in place to deal with ,,," I just have to say "PROVE IT!" Where are the business deals that mean the company is growing so fast Mr. Haas is overwhelmed. The PR that stated the biggest deal they made is in "underwriting" is absolutely lame. It's been over a month since the PR announcing this "sale". To say something like this is just ridiculous and makes me wonder if they're pumping sales deals that may or may not happen. If he PRs the deals they PR'd are done and all is wonderful I'll take back all this criticism. I'm invested here for a small amount waiting and watching but this made me wonder if these deals are ever going to pass the "underwriting" phase.
I'm don't post much on IHUB boards, When I do I try to be meaningful about it. I was reading some other biopharma stocks who were darlings whose stock price went up and up on hopes their clinical trials would prove the compounds are effective and didn't harm the participants (too much). I've read a lot of stories where the company stock price was slammed when a clinical trial didn't work out or harmed people. The good thing about LDN is that there have been many studies to show not only does it not harm it improves the lives of people who are suffering from HIV/immune disorders. I'm sold and think IMUN has a big chance to hit a HUGE home run. That's what I'm thinking about this company.